



## Advancements in Nano-Drug Delivery Systems for Effective Management of Periodontitis: A Comprehensive Review

Manisha Mishra\*, Rishabh Maurya, Meena Yadav

Mahatma Gandhi Institute of Pharmacy

### ARTICLE HISTORY

Received: 26-09-2024

Revised: 12-11-2024

Accepted: 01-12-2024

Online: 12-12-2024

### KEYWORDS

*Nano-drug delivery*

*Periodontitis*

*Nanotechnology*

*Drug formulations*

*Therapeutic agents*

*Targeted delivery*

*Oral health*

### ABSTRACT

This comprehensive review explores the transformative potential of nano-drug delivery systems in the management of periodontitis, a prevalent oral health concern. The analysis begins with an introduction, providing a foundational understanding of the evolution of nanotechnology and its application in drug delivery. The subsequent sections delve into nanoemulsion formulations, highlighting their significance in optimizing drug delivery efficiency. The integration of various therapeutic agents within nano-drug delivery systems, including antibiotics, anti-inflammatory agents, and growth factors, demonstrates the versatility of these platforms in addressing the multifaceted nature of periodontitis. The exploration of moxifloxacin as a case study illustrates the potential impact of specific drug incorporation within nano-formulations, emphasizing the relevance of tailored approaches in combating microbial complexities. Addressing challenges and considerations becomes paramount, with a focus on biocompatibility, stability, and regulatory aspects. The review then navigates through cutting-edge formulations, innovative delivery technologies, and success stories in studies, providing insights into the evolving landscape and practical applications of nano-drug delivery in periodontitis treatment. Exploring emerging trends, potential applications, and future directions underscores the transformative potential of nano-drug delivery. The concluding sections synthesize key findings, outline implications for future research, and offer reflections on the significance of this field. In summary, this analysis highlights the dynamic and promising frontier of nano-drug delivery in reshaping periodontal care. The evolving field holds promise for personalized and efficient solutions, addressing the complexities of periodontitis with tailored precision. The comprehensive insights provided in this review serve as a foundation for continued exploration and advancement in the pursuit of more effective and targeted treatments for periodontitis, ultimately contributing to the improvement of oral health outcomes.

\*Address for correspondence

Mahatma Gandhi Institute of Pharmacy

Email: [manisha.anshu1998@gmail.com](mailto:manisha.anshu1998@gmail.com)

DOI: <https://doi.org/10.55006/biolsciences.2024.4407>



## Introduction

Periodontitis is a chronic inflammatory condition affecting the supporting structures of teeth, characterized by the destruction of the periodontal ligament and alveolar bone. It is a major cause of tooth loss and has been linked to systemic health issues. The disease progression involves the formation of bacterial biofilms, triggering an immune response that, if unresolved, leads to tissue damage. Understanding the multifaceted nature of periodontitis is crucial for developing effective treatment strategies [1,2]. Since its genesis and course are so complicated, periodontitis—a chronic inflammatory disease that affects the tissues that support the teeth—has long presented serious hurdles in the field of dentistry. Traditional therapies, such as scaling, root planning, and systemic antibiotics, frequently fall short in their attempts to properly address the underlying tissue loss and inflammation. The development of nano-drug delivery devices has become a viable approach of getting around these restrictions in recent years. By delivering therapeutic compounds directly to the site of infection, these devices have the potential to improve treatment efficacy while reducing adverse effects. In order to offer a more comprehensive approach to the treatment of periodontitis, researchers are exploring the principles and uses of these nanotechnologies, which could revolutionize patient care and treatment results [7,9]. Inflammation and the breakdown of tooth-supporting tissues are the results of periodontitis, a chronic gum disease that frequently calls for more efficient treatment methods. Conventional treatments, such systemic and scaling antibiotics, may not be enough to completely control the illness. Systems for delivering drugs using nanotechnology have recently drawn


interest as a potential remedy. These cutting-edge methods make it possible to deliver therapeutic chemicals precisely to the infection site, increasing medication efficacy and lowering adverse effects. The treatment of periodontitis could be revolutionized by nano-drug delivery, which offers improved tissue penetration and regulated release [21].

One of the most prevalent dental conditions, periodontitis affects a significant percentage of people worldwide and, if untreated, can result in tooth loss. Effective management is difficult due to the pathogenesis's intricacy, which is influenced by both human immune response and microbial infection. Although systemic antibiotics and mechanical cleansing are the mainstays of current treatment methods, they frequently fail to provide localized, long-lasting therapeutic benefits. A promising substitute is provided by nano-drug delivery systems, which have the special capacity to encapsulate and release medications at specific sites. By increasing tissue penetration, reducing systemic adverse effects, and increasing the bioavailability of therapeutic drugs, these systems can treat periodontitis more effectively and precisely [35].

## Challenges in current treatment approaches

### *Microbial Complexity*

Current treatment approaches for periodontitis encounter challenges in effectively addressing the intricate microbial communities involved in disease pathogenesis. The diverse composition of bacterial biofilms, such as the red complex (*Porphyromonas gingivalis*, *Tannerella forsythia*, and *Treponema*



**Figure 1:** Stages of periodontal disease [7,8,9].

denticola), contributes to the complexity of microbial interactions within the periodontal environment [3]. This complexity poses hurdles in developing targeted therapies that can effectively combat the varied bacterial species involved in disease progression.

#### *Patient compliance and long-term efficacy*

Another significant challenge lies in ensuring patient compliance with prescribed treatment regimens and maintaining long-term therapeutic efficacy. Traditional treatment modalities often require rigorous oral hygiene practices and frequent follow-ups, demanding sustained patient commitment. Factors such as discomfort during procedures, financial constraints, and a lack of awareness contribute to challenges in sustaining long-term adherence to treatment plans [4].

#### *Prolonged drug retention*

Periodontal pockets create a challenging environment for drug delivery due to fluid dynamics and tissue barriers. NDDS can be designed to adhere to periodontal tissues or release the drug in a controlled manner, thereby prolonging drug retention in the periodontal pocket and improving treatment outcomes.

#### *Sustained Release*

NDDS can be designed to provide sustained drug release over an extended period of time. This sustained release ensures continuous therapeutic effect, reduces dosing frequency and improves patient compliance.

#### *Combination therapy*

**Table 1.** Advantages and disadvantages of LDDS.

<b>Advantages of LDDS</b>	<b>Disadvantages of LDDS</b>
Targeted delivery of drugs to periodontal pocket	Limited accessibility to deep periodontal pockets
Increased drug concentration at the site of action	Potential for local irritation or allergic reactions
Reduced systemic side effects	Difficulty in placement and retention of devices
Sustained release of drugs	Variable drug release kinetics
Improved patient compliance	Risk of microbial resistance
Enhances efficacy of mechanical therapy	Requires patient education and instruction
Minimizes need for frequent drug administration	Potential for tissue damage during insertion
Offers potential for combination therapies	Cost associated with specialized devices

The involvement of novel drug delivery systems in the treatment of periodontitis holds great promise for improving therapeutic efficacy, patient comfort, and treatment outcomes in this prevalent oral disease. Novel drug delivery systems (NDDS) play an important role in the management and treatment of periodontitis by overcoming some of the challenges associated with conventional therapies.

### **NDDS helps manage and treat periodontitis**

#### *Localized drug delivery*

NDDS allows targeted and localized drug delivery to periodontal tissues affected by periodontitis. This targeted approach ensures that therapeutic agents reach the site of infection at optimal concentrations, thereby maximizing effectiveness while minimizing systemic side effects.

#### *Improving drug stability*

Many drugs used in the treatment of periodontitis have limited stability in biological environments. NDDS can protect these drugs from degradation, thereby improving their stability and prolonging their therapeutic effects.

Periodontitis often requires a multimodal approach that includes antibiotics, anti-inflammatory drugs, and tissue regeneration drugs. NDDS allows the use of multiple drugs simultaneously or sequentially, facilitating combination therapy tailored to each patient's needs.

#### *Minimize side effects*

By delivering the drug directly to the site of infection, NDDS minimizes systemic exposure and associated side effects. This targeted delivery reduces the risk of systemic toxicity while maximizing the therapeutic effect on periodontal tissues.

#### *Improve patient compliance*

Conventional treatments for periodontitis often require frequent dental visits and complex treatment regimens, leading to poor patient compliance. NDDS can simplify treatment by reducing the frequency of medication use and minimizing invasive procedures, thereby improving patient acceptance and compliance.

#### *The potential of regenerative therapies*

NDDS offers the opportunity to deliver growth factors, peptides, and other bioactive molecules to promote periodontal tissue regeneration. These regenerative therapies aim to restore damaged periodontal tissues and promote long-term periodontal health.

### Evolution of nano-drug delivery systems

Nano-drug delivery systems have emerged as promising solutions in addressing the challenges associated with current treatment approaches for periodontitis. The evolution of nanotechnology has paved the way for the development of sophisticated delivery platforms that offer precise control over drug release, enhanced bioavailability, and targeted therapeutic effects [5].

### Rationale for nano-drug delivery In periodontitis

The rationale for employing nano-drug delivery systems in periodontitis management is rooted in their ability to overcome limitations inherent in conventional therapies. By leveraging the unique properties of nanomaterials, these systems aim to optimize drug delivery to periodontal tissues, thereby improving treatment outcomes. This transition to nanoscale formulations holds the promise of revolutionizing the way periodontitis is approached, addressing both microbial complexities and patient-related challenges [6].

### Local drug delivery system (LDDS)

Topical drug delivery systems (LDDS) play an important role in the treatment of periodontitis by delivering therapeutic agents directly to the site of infection, usually the periodontal pocket. These systems offer several advantages over systemic drug delivery, including increased efficacy, reduced systemic side effects, and improved patient compliance.

### Classification of local drug delivery systems

Local drug delivery systems can be classified based on various criteria, as outlined below-

*Based on application (Rams and Slots, 1996)*

Personally applied (patient self-care application)

- Nonsustained subgingival drug delivery
- Home oral irrigation
- Home oral irrigation jet tips
- Traditional jet tips
- Oral irrigation (water pick)

- Soft cone rubber tips (Pickpocket)

Professionally Applied in Dental Office

- Nonsustained subgingival drug delivery
- Professional pocket irrigation
- Sustained subgingival drug delivery
- Controlled release devices
- Hollow fibers
- Dialysis tubing
- Strips
- Films

*Based on Duration of Medicament Release (Greenstein and Tonetti, 2000)*

Sustained release devices

- Provide drug delivery for less than 24 hours
- Require multiple applications
- Follow first-order drug kinetics

Controlled release devices

- Drug release extends beyond 24 hours
- Administered only once

*Depending on degradability*

Non-degradable Devices (First Generation)

Degradable Devices (Second Generation)

*Classification by mechanism of action (Langer and Peppas, 1989)*

Diffusion controlled systems

- Matrices
- Reservoirs

Chemically controlled systems

- Erodible systems
- Pendant chain systems

Solvent activated systems

- Osmotic systems
- Swelling controlled systems

Release induced by external forces

### Controlled release local drug delivery system classification (Kornman, 1993)

#### Reservoirs without a rate controlling system

- Hollow fibers
- Gels
- Dialysis tubing

#### Reservoirs with a rate controlling system

- Erodible polymeric matrices
- Micro-porous polymer membranes
- Monolithic matrices
- Coated drug particles

#### Based on origin

##### Allopathic or chemical local drug delivery

##### Herbal or ayurvedic local drug delivery

##### WHO guidelines for herbal medicines

Category 1: Indigenous herbal medicines known to local communities, with established composition, treatment, and dosage.

Category 2: Well-documented herbal medicines based on long-standing usage within accepted systems (e.g., Ayurveda, Siddha, Unani).

Category 3: Modified herbal medicines meeting national regulatory requirements regarding safety and efficacy.

Category 4: Imported herbal medicines, including raw materials and products, supported by safety and efficacy data from the importing country's authorities.

#### Based on types of local drug delivery systems

- Fibers
- Films
- Strips
- Gels
- Vesicular liposomal systems
- Microparticle systems
- Nanoparticle systems

### Nano-emulsion formulations for periodontitis

Nano emulsion formulations represent an advanced method for drug delivery in the treatment of periodontitis. These colloidal systems consist of nanoscale droplets of one liquid dispersed within

another, typically stabilized by surfactants or emulsifying agents. A thorough understanding of the principles behind nano emulsions is essential for recognizing their effectiveness in enhancing drug delivery efficiency. Nano emulsions are crucial in drug delivery due to their distinctive properties. Their small droplet size creates a high surface area for interactions, which enhances the solubility and bioavailability of therapeutic agents. This section discusses how nano emulsions help to address the limitations of traditional drug delivery systems in the management of periodontitis. Analyzing the key components and characteristics of nano emulsion formulations is vital for optimizing these systems to effectively target periodontal diseases. This includes evaluating emulsifying agents, selecting appropriate oils, and considering other factors that affect stability and drug release profiles. A comprehensive examination of these elements highlights the adaptability of nano emulsion formulations for focused treatment of periodontitis.

### Therapeutic agents in nano-drug delivery

#### Antibiotics

Incorporating antibiotics into nano-drug delivery systems represents a crucial avenue for enhancing the efficacy of periodontitis treatment. Nano formulations allow for targeted delivery of antibiotics to the periodontal tissues, optimizing drug concentrations at the infection site while minimizing systemic exposure. This approach aims to address microbial complexities and combat antibiotic resistance, presenting a promising strategy for improved therapeutic outcomes in periodontitis management [9,10].

#### Anti-inflammatory agents

The utilization of anti-inflammatory agents within nano-drug delivery systems presents a promising strategy for addressing the inflammatory component of periodontitis. Nano formulations of anti-inflammatory drugs offer enhanced bioavailability and controlled release, potentially mitigating inflammation more effectively compared to traditional systemic administration. This section explores the significance of incorporating anti-inflammatory agents into nano-drug delivery systems for targeted and efficient periodontitis management [11,12].

#### Growth factors

The incorporation of growth factors into nano-drug delivery systems holds significant promise for promoting tissue regeneration and repair in periodontitis. Nano formulations of growth factors

**Table 2.** Non-degradable intra-pocket drug delivery system in periodontal diseases [36,37].

Polymer used	Method used	Form	Drugs incorporated
Polyethylmethacrylate	Moulding and compression	Film	Chlorhexidine, tetracycline, metronidazole
Ethylcellulose	Casting from ethanol or Chloroform	Film	Chlorhexidine, metronidazole, tetracycline, minocycline
Ethylene vinyl acetate Heat extrusion Fiber Tetracycline Ethyl methacrylate	Heat extrusion	Film	Tetracycline
Chlorotrimethyl ammonium methyl methacrylate	Cast from ethanol: water mixture	Film	Clindamycin

offer controlled and localized release, enhancing their therapeutic potential. This section delves into the importance of utilizing nano-drug delivery systems to harness the regenerative properties of growth factors for tissue healing and regeneration in the context of periodontal diseases [13,14].

#### *Other therapeutic agents*

Beyond antibiotics, anti-inflammatory agents, and growth factors, nano-drug delivery systems offer a versatile platform for incorporating various therapeutic agents. This category encompasses a wide range of compounds such as antioxidants, analgesics, and bone-modifying agents. Exploring the integration of diverse therapeutic agents into nano formulations provides a comprehensive approach to addressing the multifaceted nature of periodontitis, catering to specific patient needs and optimizing treatment outcomes [15,16].

#### *Targeted delivery mechanisms*

The targeted delivery mechanisms within nano-drug delivery systems play a crucial role in enhancing the precision and efficiency of periodontitis treatment. These contribute to the exploration of targeted delivery mechanisms in nano-drug delivery systems, emphasizing their significance in optimizing drug concentrations at the periodontal site while minimizing systemic exposure [17,18].

#### **Moxifloxacin in nano-drug delivery for periodontitis**

Moxifloxacin, a potent fluoroquinolone antibiotic, holds promise in nano-drug delivery systems for periodontitis treatment. Its broad-spectrum antibacterial activity, particularly against periodontal pathogens, makes it a valuable candidate. This section explores the significance of incorporating moxifloxacin into nano-drug delivery formulations, emphasizing its potential to address microbial

complexities associated with periodontitis [19,20]. Nanoformulations of moxifloxacin offer a tailored approach to enhance drug delivery efficiency. These formulations can optimize drug release kinetics, ensuring sustained therapeutic concentrations at the infection site. Investigating various nano-carriers, such as liposomes or polymeric nanoparticles, provides insights into the versatility of moxifloxacin delivery systems for targeted periodontitis management.

#### **Nano-drug delivery systems in periodontitis: a comprehensive overview**

The integration of nanoemulsion formulations within periodontitis treatment marks a significant advancement in drug delivery strategies. These colloidal systems, comprising nanosized droplets stabilized by emulsifying agents, demonstrate unique capabilities in enhancing drug solubility and bioavailability. This section delves into the seamless integration of nanoemulsion formulations, shedding light on their potential to revolutionize periodontitis management [21]. Nano-drug delivery systems offer a versatile platform for the effective delivery of therapeutic agents. Beyond antibiotics, anti-inflammatory agents, and growth factors, these systems can integrate various compounds, including antioxidants and analgesics. This diversity allows for a tailored approach to address the multifaceted nature of periodontitis, optimizing treatment outcomes based on specific patient needs [21].

The precision achieved through targeted delivery mechanisms within nano-drug delivery systems is paramount for optimizing periodontitis treatment. These mechanisms ensure the concentration of therapeutic agents at the periodontal site, minimizing systemic exposure. This section explores the various strategies employed for targeted delivery, emphasizing their role in enhancing treatment efficacy while minimizing potential side effects [22]. Moxifloxacin, a potent fluoroquinolone antibiotic, stands out as a noteworthy case study within nano-

**Table 3.** Degradable intra-pocket drug delivery system in periodontal disease [35,38].

Polymers used	Techniques used	Form	Drugs used
Hydroxypropylcellulose	Cast from ethanol solutions	Film	Tetracycline, Chlorhexidine
Polyhydroxybutyric acid polyhydroxyvalerate, poly lactic acid, polymer & copolymer	Direct compression	Compact	Tetracycline, Metronidazole
Poly ( $\epsilon$ -caprolactone) hydroxypropylcellulose	Heat extrusion	Fiber	Tetracycline
Polyethylene glycol Poly ( $\epsilon$ -caprolactone)	Casting from dichloromethane	Film	Chlorhexidine
PLGA	Solvent Evaporation	Film	Tetracycline
PLGA	Phase separation	Microsphere	Minocycline

drug delivery for periodontitis. Its broad-spectrum antibacterial activity, particularly against periodontal pathogens, positions it as a valuable candidate. Examining nano formulations of moxifloxacin provides insights into how this drug can be harnessed to address microbial complexities and enhance treatment outcomes in periodontitis [22].

Presently available nanotechnology-based treatments for periodontitis concentrate on tissue regeneration, improved antibacterial activity, anti-inflammatory benefits, and precise medication administration. Some important strategies are included below, together with information about their practicality, cost advantages, at-home usage possibilities, and future prospects.

### Drug delivery systems based on nanoparticles (NDDS)

The following are polymeric nanoparticles: These nanoparticles, which are frequently composed of chitosan, poly(lactic-co-glycolic acid) (PLGA), and polyethylene glycol (PEG), allow for the regulated release of anti-inflammatory or antibacterial drugs. They reduce systemic exposure and provide a long-lasting impact by concentrating on the periodontal pocket.

#### *Liposomes and micelles*

These lipid-based nanocarriers improve medication penetration into biofilms and provide long-lasting benefits by delivering antibacterial and anti-inflammatory drugs directly to affected regions. The antibacterial and anti-inflammatory properties of silver, gold, and zinc oxide nanoparticles directly target bacterial colonies, hence lowering infection. These may be added to mouthwashes, gels, or lozenges that release nanocarriers locally in the oral cavity for use at home.

#### *Cost-benefit*

Although a little more costly than conventional mouthwashes, they are cost-effective since they increase effectiveness and lessen the need for frequent dental appointments.

#### *Feasibility*

Clinical formulations for home-based applications are still being developed, but NDDS shows promise for at-home use because of its prolonged release and precision targeting capabilities.

#### *Regenerative gels and nanofiber scaffolds*

By imitating the extracellular matrix, electrospun nanofiber scaffolds, which are frequently composed of polycaprolactone (PCL) or polylactic acid (PLA), help to regenerate periodontal ligaments and bone.

#### *Hydroxyapatite nanoparticles*

These bioactive substances promote the formation of bone and tissue when incorporated into gels or scaffolds.

### Challenges and considerations in nano-drug delivery for periodontitis

The implementation of nano-drug delivery systems in periodontitis management is not without challenges, and biocompatibility issues stand out prominently. The interaction between nano-carriers and biological tissues raises concerns regarding potential adverse effects. Investigating the biocompatibility of these systems is crucial for ensuring their safety and efficacy in clinical applications [23]. Nano-drug delivery systems face stability challenges that can impact their effectiveness over time. Factors such as aggregation, degradation, and changes in physicochemical

properties may compromise the stability of these formulations. Addressing these challenges is imperative to guarantee the consistent and reliable performance of nano-drug delivery systems in the dynamic environment of periodontal tissues [24]. The incorporation of nano-drug delivery systems into periodontitis treatment introduces regulatory considerations. The unique characteristics of nanoformulations may necessitate specific regulatory frameworks and guidelines. Understanding and navigating these regulatory considerations is essential for the successful translation of nano-drug delivery technologies from research to clinical applications [24].

Within the realm of nano-drug delivery systems for periodontitis, a noteworthy development is the emergence of cutting-edge nano-formulations. These advanced formulations go beyond traditional approaches, incorporating novel materials and engineering techniques. Exploring the intricacies of these formulations provides insights into the forefront of nanotechnology applications, showcasing their potential to address specific challenges in periodontitis treatment [25,26]. In the landscape of nano-drug delivery systems for periodontitis, a crucial aspect is the exploration of innovative delivery technologies. These technologies aim to enhance the precision, efficiency, and patient compliance of drug administration. Investigating the latest advancements in delivery technologies sheds light on how innovations such as microneedle arrays, nanogels, or responsive drug delivery systems contribute to overcoming existing challenges in periodontitis treatment [27,28]. An essential aspect of evaluating nano-drug delivery systems for periodontitis is examining their success in preclinical and clinical studies. Understanding the outcomes of these studies provides valuable evidence regarding the safety, efficacy, and translational potential of the developed formulations. Delving into success stories in both preclinical and clinical settings allows for a comprehensive assessment of the feasibility and impact of nano-drug delivery systems in real-world applications [29,30]. Exploring emerging trends in nano-drug delivery for periodontitis unveils the latest developments shaping the field. This encompasses advancements in materials, formulation techniques, and targeted delivery strategies. Understanding these trends provides a forward-looking perspective, allowing researchers and practitioners to stay abreast of innovative approaches that may redefine the landscape of periodontitis treatment [31,32].

### **Potential applications of nano-drug delivery in periodontitis**

Examining potential applications of nano-drug delivery in periodontitis sheds light on diverse therapeutic possibilities. This includes not only

antimicrobial treatments but also regenerative therapies, immunomodulation, and personalized medicine approaches. Evaluating the versatility of nano-drug delivery systems opens avenues for tailoring treatments to specific aspects of periodontal diseases [33,34]. Delving into future directions in nano-drug delivery research for periodontitis provides insight into potential breakthroughs and unexplored avenues. This includes the integration of artificial intelligence for personalized treatments, the development of smart nanomaterials, and a deeper understanding of host-pathogen interactions. Navigating these future directions sets the stage for continued innovation in the pursuit of more effective and tailored periodontitis therapies [35,36].

### **Prospects for the present and the future**

#### *Current prospects*

Research studies and professional dental care are the primary sources of nanotechnology-based treatments. As mouth rinses and gels containing antibiotics and anti-inflammatory drugs contained in nanoparticles approach commercialisation, they may soon be available for use at home.

#### *Future prospects*

Smart nanosensors for at-home periodontal health monitoring are one example of a future breakthrough that might alert patients to inflammation or infection early. Effective periodontal care may also become widely available for at-home treatment thanks to self-assembling nanomaterials for tissue regeneration and inexpensive photodynamic therapy equipment.

#### *Cost-benefit*

Nanotechnology-based therapies are cost-effective over time due to their precise targeting, long-lasting benefits, and decreased need for frequent dental procedures, despite their high starting costs. For usage at home, particularly as mouthwashes, gels, and nano-emulsions, cost is probably affordable and is likely to improve with mass production.

### **Conclusion**

In our detailed review of nano-drug delivery systems for periodontitis, we have identified promising opportunities and potential changes in treatment approaches. The foundational concepts introduced in the early sections set the stage for a closer examination of nanoemulsion formulations, highlighting their role in enhancing drug delivery efficiency. By integrating various therapeutic agents, such as antibiotics, anti-inflammatory drugs, and

growth factors, we demonstrated the adaptability of these systems in tackling the complex challenges of periodontitis. A case study on moxifloxacin illustrated how specific drug incorporation into nano-formulations can effectively address microbial intricacies, emphasizing the importance of tailored strategies.

We also discussed the challenges associated with these systems, including biocompatibility, stability, and regulatory concerns. The later sections presented innovative formulations, advanced delivery technologies, and successful case studies, illustrating the dynamic nature and practical uses of nano-drug delivery in treating periodontitis. By examining emerging trends and future possibilities, we highlighted the transformative potential of nano-drug delivery systems. The concluding sections synthesized our findings, emphasizing the significance of this field and outlining key insights, implications for future research, and final thoughts.

### Contribution of authors

All authors have contributed equally to writing the article.

### Acknowledgments

None

### Conflict of Interest

None

### Funding

None

### References

1. Tonetti MS, Jepsen S, Jin L. Impact of the global burden of periodontal diseases on health, nutrition, and wellbeing of mankind: A call for global action. *J Clin Periodontol.* 2017;44(5):456-462.
2. Hajishengallis G, Lamont RJ. Beyond the red complex and into more complexity: The polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. *Mol Oral Microbiol.* 2012;27(6):409-419.
3. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. *Lancet.* 2005;366(9499):1809-1820.
4. Kornman KS, Papapanou PN. Clinical application of the new classification of periodontal diseases: Ground rules, clarifications and "gray zones". *J Periodontol.* 2008;79(8):1347-1359.
5. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. *Nat Rev Drug Discov.* 2005;4(2):145-160.
6. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. *Adv Drug Deliv Rev.* 2005;57(15):2106-2129.
7. McClements DJ. Design of nano-laminated coatings to control bioavailability of lipophilic food components. *Pure Appl Chem.* 2011;83(4):1021-1037.
8. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. *Adv Drug Deliv Rev.* 2012;64:175-193.
9. Gajendiran M, Saraswathi R, Vijayalakshmi R. Nanoemulsion: An advanced mode of drug delivery system. *3 Biotech.* 2018;8(3):120.
10. Chen H, Khemtong C, Yang X, Chang X. Gd-nanoparticles functionalized with folic acid as a bimodal imaging agent for cancer cell targeting. *Mol Imaging.* 2010;9(3):142-150.
11. Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and RNA. *Front Pharmacol.* 2014;5:77.
12. Hua S. Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. *Front Pharmacol.* 2014;5:254.
13. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. *Nanomedicine (Lond).* 2007;3(1):20-31.
14. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: General approaches and a review of recent developments. *J R Soc Interface.* 2011;8(55):153-170.
15. Kim S, Nishimoto SK, Bumgardner JD, Haggard WO, Gaber MW. Nanostructured polymer coatings for local and sustained delivery of the antibiotic ciprofloxacin. *Biomaterials.* 2008;29(33):4739-4748.
16. Zhang L, Pornpattananangkul D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. *Curr Med Chem.* 2010;17(6):585-594.
17. Torchilin V. Drug targeting. *Eur J Pharm Sci.* 2000;11.
18. Torchilin VP. Multifunctional nanocarriers. *Adv Drug Deliv Rev.* 2011;63(4-5):222-235.
19. Yamaguchi H, Kojima K, Inui T, Nakashima H, Yamamoto N. Efficacy of moxifloxacin against periodontopathic bacteria in vitro and in human periodontal ligament cells. *J Periodont Res.* 2013;48(3):377-382.
20. Langtry HD, Campoli-Richards DM. Moxifloxacin. *Drugs.* 1999;58(4):617-647.
21. Miranda PV, de Araujo RF Jr, Leite AM, Sabino

- JP, Silva HC, Monteiro JC. "Nanotechnology in periodontal disease therapy: A systematic review." *J Appl Oral Sci.* 2021, Apr 5;29.
22. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. *Adv Drug Deliv Rev.* 2005;57(15):2106-2129.
  23. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. *Nat Rev Drug Discov.* 2006;5(2):145-160.
  24. Jain RK, Stylianopoulos T, Munn LL. Role of normalization in tumor pathophysiology: Theoretical framework, methods, and challenges. *Am J Physiol Cell Physiol.* 2014;307(7).
  25. Mitragotri S, Lahann J. Physical approaches to biomaterial design. *Nat Mater.* 2009;8(1):15-23.
  26. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. *Nat Rev Mater.* 2016;1(12):16071.
  27. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. *ACS Nano.* 2009;3(1):16-20.
  28. Hua S, Wu SY. The use of lipid-based nanocarriers for targeted pain therapies. *Front Pharmacol.* 2013;4:143.
  29. Torchilin VP. Multifunctional nanocarriers. *Adv Drug Deliv Rev.* 2014;66:2-25.
  30. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol.* 2015;33(9):941-951.
  31. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. *Bioeng Transl Med.* 2019;4(3).
  32. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. *Chem Rev.* 2016;116(4):2602-2663.
  33. Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. *J Control Release.* 2011;153(3):198-205.
  34. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. *Nat Nanotechnol.* 2007;2(12):751-760.
  35. Chomoucka J, Drbohlavova J, Huska D, Adam V. Nanocarriers for anticancer drugs-new trends in nanomedicine. *Curr Drug Metab.* 2014;15(6):547-564.
  36. Peppas NA, Khademhosseini A. Make nanobots from natural materials. *Science.* 2016;351(6278):460-461.
  37. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nat Rev Drug Discov.* 2014;13(11):813-827.
  38. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges, and opportunities. *Nat Rev Cancer.* 2017;17(1):20-37.
  39. Langer R. Drug delivery and targeting. *Nature.* 2015;526(7573):7498.